Prime Medicine, Inc. (PRME)

Every figure this model derived for PRME, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 797,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 95,071,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 96,804,000 AssetsCurrent 2026-06-30
current liabilities 31,692,000 LiabilitiesCurrent 2026-06-30
equity 39,809,000 StockholdersEquity 2026-06-30
ocf -156,051,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 4,632,000 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 26,771,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up PRME on one particular measure came for.

RatioValue
current ratio4.07
current ratio reported3.05
deferred revenue growth-4.58
dilution pct25.45
revenue growth55.28
revenue growth per share23.78
rule of 40-4187.38
sbc pct revenue577.96

What to be careful about

What this model itself distrusts about PRME's figures. Written by the derivation as it ran, not added afterwards.